SEVEN FLEET CAPITAL MANAGEMENT LP
Q1 2026 Form 13-F
MOUNTAIN VIEW, DELAWARE
CIK 0002092021
· CRD 335203
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2025
$318.3M Reported Value Total
SEVEN FLEET CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $434,581,362, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $434.6M gross asset value
Hedge Fund: $263.1M · Other: $171.4M
Source: Form ADV filed 2026-07-06
Reported value
$318.3M
Quarter over quarter
+35.8%
Holdings
115
Top-10 concentration
51.3%
Filing Structure
Reports holdings for
- DV Trading LLC · File #028-26555 · since Q4 2025 · declared by one filing
Key People
Form ADV owners & control persons
Brian Guan-Chyun Liu
MANAGING MEMBER
Rod Seung-Hwan Lim
LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $318.3M |
| Positions | 115 |
| Change in reported value | +115.4% |
| New positions | 59 |
| Exited positions | 29 |
| Position turnover | 61.1% |
| Top-10 concentration | 51.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 15, 2026
|
96 | $605.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
115 | $318.3M |
|
Q4 2025 13F
Filed Feb 26, 2026
|
85 | $147.8M |
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $97.4M | 30.61% |
| 2 | TNGX TANGO THERAPEUTICS INC | $10.5M | 3.3% |
| 3 | RVMD REVOLUTION MEDICINES INC | $7.9M | 2.47% |
| 4 | TYRA TYRA BIOSCIENCES INC | $7.5M | 2.35% |
| 5 | LQDA LIQUIDIA CORPORATION | $7.1M | 2.23% |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | $7.1M | 2.23% |
| 7 | IPSC CENTURY THERAPEUTICS INC | $6.7M | 2.09% |
| 8 | ELVN ENLIVEN THERAPEUTICS INC | $6.4M | 2.02% |
| 9 | PCVX VAXCYTE INC | $6.3M | 1.98% |
| 10 | TNGX TANGO THERAPEUTICS INC | $6.3M | 1.98% |
| 11 | COGT COGENT BIOSCIENCES INC | $5.8M | 1.81% |
| 12 | AVTX AVALO THERAPEUTICS INC | $5.4M | 1.69% |
| 13 | NERV MINERVA NEUROSCIENCES INC | $5.4M | 1.68% |
| 14 | CGON CG ONCOLOGY INC | $5.1M | 1.61% |
| 15 | PHVS PHARVARIS N V | $4.9M | 1.53% |
| 16 | ABVX ABIVAX SA | $4.8M | 1.51% |
| 17 | DNTH DIANTHUS THERAPEUTICS INC | $4.6M | 1.43% |
| 18 | PHVS PHARVARIS N V | $4.1M | 1.28% |
| 19 | CYTK CYTOKINETICS INC | $4.0M | 1.27% |
| 20 | SLNO SOLENO THERAPEUTICS INC | $3.9M | 1.22% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.